Evidence map›Paper›PMID 40709577›Full record

ArticleHuman brain mapping2025

Altered EEG Response of the Parietal Network in Asymptomatic C9orf72 Carriers.

Stefan Dukic, Kevin van Veenhuijzen, Henk-Jan Westeneng, Roisin McMackin, Ruben P A van Eijk, Boudewijn T H M Sleutjes, Bahman Nasseroleslami, Orla Hardiman, Leonard H van den Berg

Abstract read
In one paragraph

Article in Human brain mapping, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stefan DukicDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0001-7867-2876
Kevin van VeenhuijzenDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-4386-2351
Henk-Jan WestenengDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0001-7138-3852
Roisin McMackinAcademic Unit of Neurology, School of Medicine, Trinity College Dublin, University of Dublin, Dublin, Ireland.ORCID 0000-0002-9223-2241
Ruben P A van EijkDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-7132-5967
Boudewijn T H M SleutjesDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0001-6618-3573
Bahman NasseroleslamiAcademic Unit of Neurology, School of Medicine, Trinity College Dublin, University of Dublin, Dublin, Ireland.ORCID 0000-0002-2227-2176
Orla HardimanAcademic Unit of Neurology, School of Medicine, Trinity College Dublin, University of Dublin, Dublin, Ireland.ORCID 0000-0003-2610-1291
Leonard H van den BergDepartment of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-5203-9674

Funding

Stichting ALS Nederland AV2022-0004Stichting ALS Nederland AV2022-0005The ALS Association/ALS Finding A Cure 23-PPG-674-1
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron degeneration. Around 10% of cases have a genetic basis, with the C9orf72 hexanucleotide repeat expansion being the most common cause in individuals of European ancestry. Detecting early alterations in at-risk individuals could aid in identifying biomarkers for timely diagnosis and intervention. In this study, we investigated electrophysiological changes in asymptomatic C9orf72 mutation carriers using EEG, focusing on cognitive and motor networks, as these individuals are at risk of developing impairments in both domains. This study included 87 asymptomatic family members (AFM) of patients with familial C9orf72 ALS, comprising 37 individuals carrying the pathological repeat expansion (C9+) and 50 without it (C9-). High-density EEG was recorded during the sustained attention to response task (SART), which is a Go/NoGo paradigm that engages the frontoparietal and motor networks. Task performance was recorded and six behavioral measures were extracted: NoGo accuracy, Go accuracy, total accuracy, anticipation error, average response time, and response time variability. Analyses were conducted on EEG data in both sensor- and source-space, using stimulus- and response-locked data. The stimulus-locked Go and NoGo data were analysed within two time windows: 180-350 ms (N2) and 300-600 ms (P3), while response-locked Go data were analysed within a -100 to 100 ms time window. Linear mixed models were used to quantify differences between groups, incorporating familial pedigree to control for between-subject dependencies. While the two groups did not significantly differ in any SART performance measures, EEG analyses revealed differences. During the stimulus-locked N2, significant differences were observed in sensor-space, primarily in central electrodes during both NoGo and Go conditions, with C9+ AFM exhibiting an increased negative potential. Source analysis confirmed these findings and localized the increased activity in the bilateral precuneus and superior parietal regions. Further analysis of the response-locked data supported the involvement of the same posterior regions. No significant relationships were found between these EEG observations and SART performance. These findings provide the first evidence of EEG changes in AFM carrying the C9orf72 repeat expansion. The observed functional changes in the parietal regions may reflect genotype-related effects on the motor control network, potentially contributing to early pathophysiology. In contrast, clinical assessments and task performance did not differ between groups, suggesting that our EEG findings may hold promise as biomarkers for monitoring the risk of conversion to symptomatic disease and warrant further exploration to assess their predictive value for future symptom onset.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinNerve NetParietal LobeAdultAgedElectroencephalographyFemaleHeterozygoteHumansMaleMiddle AgedReaction TimeC9orf72 ProteinC9orf72 protein, humanALSamyotrophic lateral sclerosisasymptomaticC9orf72EEGsustained attention to response task

Identifiers

PMID40709577
PMCPMC12290479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.